Molecular Vision: Riemens, Mol Vis 2012; 18:797-802. Table 1

Table 1. General characteristics of patients after allogeneic stem cell transplantation (allo-SCT).

Patient characteristics	Total, allo-SCT patients (n=34)	*Ocular GvHD (n=16)**	No Ocular GvHD (n=18)
Mean age (yrs)±SD (Minimum, maximum)	51.5±13.8 (18–71)	50.1±15.8 (23–71)	52.7±12.1 (18–64)
Gender, n (%)
Male	22/34 (65%)	13/16 (81%)	9/18 (50%)
Female	12/34 (35%)	3/16 (19%)	9/18 (50%)
Follow-up last transplantation, n (%)
≤100 days	15/34 (44%)	3/16 (19%)	12/18 (67%)
>100 days	19/34 (56%)	13/16 (81%)	6/18 (33%)
Type of transplant, n (%)
Matched related donor	11/34 (32%)	9/16 (56%)	2/18 (11%)
Matched unrelated donor	23/34 (68%)	7/16 (44%)	16/18 (89%)
TBI, n (%)
Yes	27/34 (79%)	13/16 (81%)	14/18 (78%)
Unknown	2/34 (6%)	1/16 (6%)	1/18 (6%)
TBI and chemotherapy (ATG or FLU)
Yes	27/34 (54%)	13/16 (81%)	14/18 (78%)
Unknown	2/34 (4%)	1/16 (6%)	1/18 (6%)
Type of disorder, n (%)
Multiple myeloma	10/34 (29%)	5/16 (31%)	5/18 (28%)
AML	9/34 (26%)	1/16 (6%)	8/18 (44%)
NHL	5/34 (15%)	3/16 (19%)	2/18 (11%)
ALL	3/34 (9%)	1/16 (6%)	2/18 (11%)
CLL	1/34 (3%)	1/16 (6%)	0/18 (0%)
HL	1/34 (3%)	1/16 (6%)	0/18 (0%)
CML	1/34 (3%)	1/16 (6%)	0/18 (0%)
Other	4/34 (12%)	3/16 (19%)	1/18 (6%)

n, Number of patients; FLU, Fludarabine; CML, Chronic myelcytic leukemia; ATG, Anti-thymocyte globulin; ALL, Acute lymphblastic leukemia; Allo-SCT, allogeneic stem cell transplantation; AML, Acute myeloblastic leukemia; CLL, Chronic lymphocytic leukemia; GvHD, Graft-verus-Host-Disease; HL, Hodgkin’s lymphoma; NHL, non-Hodgkin’s lymphoma; SD, standard deviation; TBI, Total body irradiation. *diagnosed according to the National Institute for Health consensus criteria [3].